drugset / Trial / NCT03281694
The Use of AVL-3288 to Potentiate the Attention-Enhancing Effects of Low-Dose Nicotine
NaSingle-groupOpen-labelBasic science
Summary
Single-center, randomized, double-blind, placebo-controlled, proof-of-principle study to evaluate potential cognitive benefits of a single oral dose of AVL-3288 (3 mg) in the presence and absence of transdermal nicotine (7 mg/24 hrs) in healthy non-smokers, while monitoring the safety and tolerability of AVL-3288.
Timeline
- Start
- 2018-05
- Primary completion
- 2019-02
- Completion
- 2019-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AVL-3288 | Small molecule | 3 mg | Oral |
| Subject | Nicotine | Unknown | 7 mg | Other |
Indications
No indication recorded.